Yen Wen Yu
Vermogen: 4 M $ op 30-09-2026
Vermogen: 4 M $ op 30-09-2026
Mr. Yen Wen Yu is a Chief Operating Officer at Disc Medicine, Inc. Mr. Yu was previously employed as a Vice President-Finance & Operations by Qpex Biopharma, Inc. and a VP-Strategic Planning & Corporate Development by The Medicines Co. He received his undergraduate degree from Harvard College and an MBA from The Wharton School of the University of Pennsylvania.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
DISC MEDICINE, INC. 0,14% | 25-08-2026 | 54.324 ( 0,14% ) | 4 M $ | 30-09-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| DISC MEDICINE, INC. | Operationeel Directeur | 07-02-2024 |
| Bedrijven | Functie | Einde |
|---|---|---|
Qpex Biopharma, Inc.
Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery, development and regulatory services for clinical-stage biopharmaceutical company | Oprichter | 01-07-2020 |
| THE MEDICINES COMPANY | Corporate Officer/Principal | 01-07-2018 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
The Medicines Co.
The Medicines Co. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for acute cardiovascular care | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard College
Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Qpex Biopharma, Inc.
Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery, development and regulatory services for clinical-stage biopharmaceutical company | Health Technology |
Disc Medicine, Inc.
Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau